Yichang, China – Yichang Tianrui Biopharm Co., Ltd., a premier specialty API manufacturer and a wholly-owned subsidiary of the Humanwell Healthcare Group, announces a pivotal regulatory achievement for its high-purity Letermovir API (CAS: 917389-32-3). The company's Letermovir drug dossier has been officially accepted and assigned the "I" (Under Inspection) status by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
This "I" designation is a decisive step in the regulatory journey, confirming the CDE has initiated the formal review and inspection process for the associated Drug Master File (DMF). It serves as a direct precursor to the on-site Good Manufacturing Practice (GMP) inspection, positioning Yichang Tianrui for a swift certification outcome. This milestone clearly signals to global pharmaceutical partners that Yichang Tianrui Biopharm is on the fast track to obtaining full China NMPA GMP certification for its Letermovir production lines, ensuring a reliable, compliant, and high-quality API supply.
Letermovir: A Paradigm Shift in CMV Prophylaxis for Transplant Patients
Letermovir is a groundbreaking antiviral agent specifically indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). It represents a significant therapeutic advance with distinct clinical benefits:
Novel Mechanism of Action: Unlike traditional CMV therapies that target viral DNA polymerase, Letermovir inhibits the viral terminase complex, a key enzyme involved in viral DNA packaging and processing. This unique mechanism offers a powerful, targeted approach with a low risk of cross-resistance to existing antiviral drugs.
Superior Efficacy with Improved Safety Profile: Clinical trials have demonstrated Letermovir's superior efficacy in preventing clinically significant CMV infection compared to placebo, with a markedly favorable safety and tolerability profile. It is not associated with the classic dose-limiting toxicities of traditional agents, such as myelosuppression or renal impairment, making it a cornerstone for protecting vulnerable transplant patients.
Prophylactic Standard of Care: Its primary use as a prophylactic therapy allows for the prevention of CMV reactivation before it can cause disease, reducing morbidity, mortality, and healthcare costs associated with CMV management post-transplant. This positions it as an essential component in modern transplant protocols.
Why Source Letermovir API from Yichang Tianrui Biopharm?
The attainment of the "I" status is a testament to our technical rigor and commitment to excellence. Partnering with Yichang Tianrui for your Letermovir API supply offers a strategic, high-value proposition:
Accelerated Regulatory Pathway: Our advanced position in the NMPA review cycle places us at the forefront of GMP certification for Letermovir API in China. We offer partners a first-to-market advantage with a supply chain that is both compliant and audit-ready for global regulatory submissions.
World-Class, Specialized Infrastructure: Our Letermovir is produced in our state-of-the-art Phase I facility, a $112 million investment featuring dedicated HPAPI-capable production lines. Equipped with advanced platforms like precision lyophilization and spray drying, we ensure the stringent process control required for this complex molecule, guaranteeing exceptional purity, stability, and consistency.
Inherent Expertise in Antiviral APIs: As evidenced by our growing portfolio including Maribavir, we have developed specialized expertise in the synthesis and scale-up of complex antiviral compounds. Our technical team possesses deep knowledge of the specific challenges involved, ensuring robust and reliable manufacturing processes.
End-to-End Supply Chain Security & Scalability: From key advanced intermediates to the finished API, we maintain stringent control over our vertically integrated supply chain. This, supported by our expansive 330-acre campus, ensures uninterrupted supply, competitive scalability, and resilience to market fluctuations, enabling you to meet long-term commercial demand with confidence.
A Trusted CDMO Partner from the Humanwell Ecosystem: Backed by the global reputation and R&D excellence of the Humanwell Group, we offer more than just API supply. We provide comprehensive CDMO/CMO solutions, supporting partners with process optimization, analytical development, and customized manufacturing services tailored for high-potency molecules like Letermovir.
With the "I" status firmly secured, Yichang Tianrui Biopharm is ready to be the strategic partner of choice for pharmaceutical companies worldwide seeking a dependable source of GMP-certified Letermovir API.
We invite innovator and generic pharmaceutical companies to engage with us for pre-commercial and commercial supply agreements. Partner with us to secure the foundation of your CMV prophylactic therapies with an API supplier committed to quality, innovation, and partnership.
About Yichang Tianrui Biopharm Co., Ltd.
Yichang Tianrui Biopharm Co., Ltd., established in 2022, is a dynamic specialty API and HPAPI manufacturer under the Humanwell Healthcare Group (SSE: 600079). Headquartered in the Baiyang Bio-industrial Park, Yichang High-Tech Zone, the company is executing a visionary $277 million, 330-acre campus development. Its operational Phase I facility, representing a $112 million investment, features international-standard GMP workshops and dedicated production lines. Yichang Tianrui is dedicated to the research, production, and global supply of specialty APIs, advanced intermediates, and veterinary APIs, while delivering elite CDMO services to the international pharmaceutical industry.
Contact: Ivy Zhou
Telephone number/Wechat: +86 15072537837
Whatsapp: +86 15672498608
